Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913497 · ClinicalTrials.gov registry record · Phase 4
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
A Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00913497: Completed Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Corewell Health West.
NCT00913497 is a Phase 4 study of Type 1 Diabetes Mellitus that has completed, run by Corewell Health West. The registered enrollment target is 16 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00913497, a Phase 4 study of Type 1 Diabetes Mellitus, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
Primary Outcome
Compare average blood glucose at 2 and 4 hours post prandial minus blood glucose at baseline (prior to eating)
Conditions Studied
Interventions
- DRUG insulin aspart
- DRUG insulin glulisine
Study Locations (1)
Michigan
- Helen DeVos Childrens Hospital - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
What the finished NCT00913497 record still lists
NCT00913497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which insulin aspart is the first listed.
NCT00913497 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00913497 about?
NCT00913497 is a clinical study titled "The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children". To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
What is the current status of trial NCT00913497?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2009-06. Estimated completion is 2012-01.
What conditions does trial NCT00913497 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00913497?
The interventions under investigation include: insulin aspart (DRUG), insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT00913497?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00913497 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00913497's enrollment target sits among peer trials
16 97th of 112 higher than 12 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 4
-
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
COMPLETED · Phase 4
-
Detemir: Role in Type 1 Diabetes
COMPLETED · Phase 4
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia